Industrial Biotechnology Catalyst: Open Call

News

Industrial Biotechnology Catalyst: Open Call

26 Feb, 2014

Published over 12 years ago. See the latest and most current information on News.

Applications are now open for the Industrial Biotechnology Catalyst supported by BBSRC, the Technology Strategy Board (TSB) and the Engineering and Physical Sciences Research Council (EPSRC).

The first IB Catalyst call will fund support for major integrated research and development projects involving collaborations between the academic and business communities. The IB Catalyst is modelled on the MRC/TSB Biomedical Catalyst and will encourage major challenge-led research projects derived from the networking activities.

The IB Catalyst will allocate funds of up to £45M in the first year, to support collaborative R&D efforts between business and academia or cross-disciplinary academic collaboration funded by the BBSRC (£20M), TSB (£15M), and EPSRC (£10M).

Total project sizes can range from up to £250k for feasibility studies to up to £10M for experimental development.

The aim is to build this investment to a scale comparable to the £180M Biomedical Catalyst already in existence.

The linking of BBSRC, TSB and EPSRC investments in Industrial Biotechnology will take to the next level a powerful alignment and focus that has been building over the last three years.

Registration Deadline 7th May 2014

For more information visit: www.bbsrc.ac.uk/business/collaborative-research/tsb-competitions/ib-catalyst.aspx.

Latest News

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
FM approval strengthens intelligent fixed gas detection for refineries and petrochemical plants
Explore more Arrow
Pollution Solutions Online
Slurry grant a fossil fuel failure?
Explore more Arrow
Petro Online
Precision by weight: The critical role of gravimetric blending in fuel certification
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow